Results for this period
First quarter1 April 2026 to 30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
There was no business revenue because there was no milestone income or other such revenue. Business expenses increased due to the increase in the number of medical institutions and cases in clinical trials, as well as the manufacture of active pharmaceutical ingredients and drug products for the next trial.
None. The notes regarding the going concern assumption state, “There are no applicable matters.”
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Operating profit | -420 million yen |
| Ordinary income | -422 million yen |
| Profit attributable to owners of the parent | -422 million yen |
| Net income per share | △30.23 |
| Equity ratio | End of the current fiscal period -131.8 / End of previous period 12.6 |
| Total assets | 150 million yen |
| Net assets | -196 million yen |
| Full-year earnings forecast | Net Sales Not disclosed / Operating profit -1,330 million yen / Ordinary income -1,340 million yen / Net income -1,350 million yen |
| Annual Dividend Forecast | 0 yen → 0 yen（0.0%） |
| Depreciation and amortization | 343 thousand yen |
| Disclosure regarding the going concern assumption | None. The notes regarding the going concern assumption state, “There are no applicable matters.” |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | The company resolved to issue the 12th Stock Acquisition Rights and the 3rd Unsecured Bonds through a private placement, and payment was completed for ¥1.4 million in stock acquisition rights and ¥150 million in unsecured bonds. In addition, the deficit in retained earnings carried forward was covered through a reduction in capital and capital reserves and the appropriation of surplus. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 14,305,000 Shares |
| Treasury Shares at Period-End | 198 Shares |
| Factors Behind Changes in Business Performance | There was no business revenue because there was no milestone income or other such revenue. Business expenses increased due to the increase in the number of medical institutions and cases in clinical trials, as well as the manufacture of active pharmaceutical ingredients and drug products for the next trial. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.There was no business revenue because there was no milestone income or other such revenue. However, business expenses increased as the company proceeded with clinical trials in its development pipeline, where the number of medical institutions and cases increased, and with the manufacture of active pharmaceutical ingredients and drug products for the next trial.